Ratan Tata: Indian tycoon who built a global empire
Tata, who originally planned to be an architect, was working in the US when his grandmother asked him to return to India and join the family business.
In 1991, Tata took over the leadership of the company as India opened its economy to global markets. (Photo: Getty Images)
By EasternEyeOct 10, 2024
RATAN TATA, the Indian industrialist who transformed the Tata Group into a global conglomerate, has died at the age of 86. Known for his leadership in expanding the group’s operations from software to luxury cars, Tata’s tenure helped shape the company’s international reputation.
Tata, who originally planned to be an architect, was working in the United States when his grandmother asked him to return to India and join the family business. He began his career in 1962, working on the shop floor near blast furnaces while staying in a hostel for apprentices.
"It was terrible at that time, but if I look back at it, it's been a very worthwhile experience because I have spent years hand-in-hand with the workers," Tata said in a rare interview.
In 1991, Tata took over the leadership of the company as India opened its economy to global markets. His 21-year tenure saw the Tata Group acquire global brands such as Jaguar and Land Rover.
Expansion and challenges
Tata’s leadership also saw the group expand into new sectors. In 2004, Tata Consultancy Services went public, and Tata soon announced plans for the company to expand its global presence. His vision led to acquisitions such as Britain's Tetley Tea and the Anglo-Dutch steel firm Corus.
The 2008 acquisition of Jaguar and Land Rover for £1.75 billion brought Tata Group into the global spotlight. However, the Corus acquisition faced challenges due to falling European steel demand.
Tata's dream of creating the world’s cheapest car, the Tata Nano, failed to meet market expectations in India, where status-conscious buyers were reluctant to own what was seen as a "poor man’s car."
Ratan Tata poses in front of the Tata Nano car during the launch in New Delhi, 10 January 2008. (Photo: Getty Images)
Despite these setbacks, Tata’s overall achievements were significant, with the group’s revenues rising from £4.58 billion to £76.34 billion, and its presence extending to over 100 countries.
Controversies and retirement
Though respected in India’s corporate world, Tata was not without controversy. In 2011, he was questioned in connection with a telecom licensing investigation, but the group was cleared of any wrongdoing.
Tata stepped down in 2012, with praise from industry leaders, including Rahul Bajaj, who called his tenure "outstanding." Reflecting on his work, Tata said, "I have devoted my life, as best I could, to the welfare of the group."
Rata Tata's 21-year tenure saw the Tata Group acquire global brands such as Jaguar and Land Rover. (Photo: Getty Images)
Brief return and later years
Tata’s retirement was brief. In 2016, he returned to lead the group temporarily after the dismissal of his successor, Cyrus Mistry, which led to a public dispute. Mistry’s sacking and the fallout from the incident hit the group’s reputation and stock prices.
After stepping away again, Tata welcomed Air India back to the group in 2021, years after its nationalisation. In his later years, Tata focused on charitable efforts and investing in start-ups.
Tata remained active in his personal life, joining Instagram at 81 and sharing his interests in cars, flying, and dogs.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.